Amicus is focused on the following five key strategic priorities in 2023: Sustain double-digit Galafold revenue growth; Secure FDA, EMA, and MHRA approvals for AT-GAAh Initiate successful global launches of AT-GAA; Advance next generation pipeline programs; Maintain strong financial position on path to profitability.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FOLD:
- Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Amicus receives positive CHMP opinion for Pombiliti for LOPD
- Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
- Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
